Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses its research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is...
Bad movement today,
unfortunately due to a "bad" annual finance report, personally I do think the management has taken a good decision with cost reduction for the next 2 years.
Consolidation of R&D activities in one location (Israel). Positions and operations eliminated will also reduce overlapping R&D and G&A activities in Israel and the United States;
A 35%...
HOLON, Israel, Jan. 14, 2019 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG, will be featured in a trial-in-progress poster at The ASCO-SITC Clinical Immuno-Oncology...
macd about to cross
cci and percent r upper band get our book on amazon for reasons why 40 years experience
relative strength strong in strong group
money flow rising
in cloud on weekly
above cloud see in our book on amazon important reason of cloud macd about to cross
relative strength strong
money flow excellent please diversify between candidates use good money
management in our book
profit target at 6.60 USD. I suppose we have an HPS setup with the trend line divergences, the undersold stochastics indicator, the very much undersold relative strength index and the MACD line intersecting the signal line
It seems to me that it will bounce back off the support line one more time and possibly have a breakout over the resistance level. good luck...
